DEF 14A: Provectus Biopharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Share Reduction

Provectus Biopharmaceuticals is asking stockholders to approve a reverse stock split and a corresponding reduction in the number of authorized shares to improve marketability and align share structure.

Summary

• Provectus Biopharmaceuticals is seeking stockholder approval for several key proposals at its 2025 Annual Meeting.
• The proposals include the election of four directors, an advisory vote on executive compensation, and the ratification of the selection of CBIZ CPAs P.C. as the independent auditor.
• A significant proposal involves authorizing the Board to implement a reverse stock split of the company's common and preferred stock at a ratio between 1-for-10 and 1-for-50.
• If the reverse stock split is approved, the Board also seeks authorization to reduce the number of authorized shares of common and preferred stock by the same ratio.
• The Board believes the reverse stock split could improve the marketability and liquidity of the company's stock.
• The company is using internet availability for proxy materials to reduce costs and environmental impact.
• The annual meeting is scheduled for June 18, 2025, in Knoxville, Tennessee.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily presenting factual information about the company's upcoming annual meeting and proposals. The potential benefits of the reverse stock split are mentioned, but so are the risks, resulting in a balanced outlook.

Positives

• The Board believes a reverse stock split could improve the marketability and liquidity of the company's stock.
• The company is using internet availability for proxy materials to reduce costs and environmental impact.

Negatives

• The company's common stock currently trades on the OTC Bulletin Board, indicating it does not meet the listing requirements of national securities exchanges.
• The company has a history of operating at a loss and needs additional capital to implement its plan of operations.
• The company has a history of operating at a loss and needs additional capital to implement its plan of operations.

Risks

• The Board cannot predict the effect of the Reverse Stock Split upon the market price for our shares of common stock, and the history of similar reverse stock splits for companies in like circumstances has varied.
• If the Reverse Stock Split is implemented, the resulting per-share price may not attract institutional investors, investment funds or brokers and may not satisfy the investing guidelines of these investors or brokers, and consequently, the trading liquidity of our common stock may not improve.
• The market price of our shares of common stock may also be affected by the Company's performance and other factors, the effect which our Board cannot predict.
• In the future, the market price of the shares of our common stock following the Reverse Stock Split may not exceed or remain higher than the market price of the shares of our common stock prior to the Reverse Stock Split.
• If the Reverse Stock Split is effected and the market price of the shares of our common stock then declines, the percentage decline may be greater than would occur in the absence of the Reverse Stock Split.
• Additionally, the liquidity of the shares of our common stock could be adversely affected by the reduced number of shares that would be outstanding after the implementation of the Reverse Stock Split.
• The Reverse Stock Split may result in some stockholders owning odd lots of less than one hundred (100) shares of common stock.
• Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions in round lots of even multiples of one hundred (100) shares.

Future Outlook

The company anticipates needing to raise additional capital through equity financing and may issue additional shares of common stock and/or preferred stock to satisfy the 2025 Financing.

Management Comments

• The Board believes that we can improve the marketability and liquidity of our common stock if the share price of the common stock is increased to a range of $1.00 to $3.00 per share.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors.

Management Changes

Related Party Transactions

• Heather Raines was issued a $100,000 note on 8/16/2021.
• Edward Pershing was issued notes totaling $450,000 in 2024.
• Edward Pershing was issued notes totaling $715,000 in 2024.
• Edward Pershing was issued notes totaling $455,000 in 2025.

Stakeholder Impact

• The reverse stock split and share reduction could impact stockholders' ownership percentages and the market value of their holdings.
• The potential for improved marketability and liquidity could benefit stockholders.
• The company's ability to raise additional capital could impact its future operations and growth, affecting employees, customers, and suppliers.

Next Steps

• Stockholders will vote on the proposals at the 2025 Annual Meeting on June 18, 2025.
• The Board will determine the specific ratio for the reverse stock split, if approved.
• The company will file amendments to its certificate of incorporation to effect the reverse stock split and share reduction, if approved.
• The company will notify stockholders of the reverse stock split implementation and provide instructions for exchanging stock certificates.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, stockholders, authorized shares, executive compensation, directors, CBIZ, preferred stock, common stock, Provectus Biopharmaceuticals